Dergoing Transrectal Ultrasound (TRUS) guided prostate biopsy. Abbreviations AS: Active surveillance; EAU: European Association of Urology; HRQOL: Health associated quality of life; MRI: Magnetic resonance imaging; PCa: Prostate Cancer; PIL: Patient details leaflet; ProBE: Prostate Biopsy Effects study; Shield: Prostate testing for cancer and Therapy trial, International Regular Randomised Controlled Trial Quantity KGF/FGF-7, Human (163a.a, His) 20141297; PSA: ProstateWade et al. BMC Well being Solutions Analysis (2015) 15:Web page 9 ofspecific antigen; RCT: Randomised controlled trial; RP: Radical prostatectomy; TRUS-Bx: Transrectal ultrasound guided biopsy. Competing interests The authors declare they’ve read and understood the BMC Well being Solutions Analysis policy on declarations of interest and have no interests to declare. Authors’ contributions JW and JLD conceived the study and have been primarily responsible for the evaluation plus the completed manuscript. JW, JD, KNLA and CES performed RNase Inhibitor Storage interviews and contributed to evaluation; DJR, JLD, JAL, and FCH devised the ProBE study protocol and arranged integration in to the ongoing Protect study. Guard study funding was obtained by FCH, DEN and JLD. CM supplied statistical experience within ProBE, contributed to data analysis and interpretation and together with DJR, JAL and JH contributed to development in the revised patient facts. MLG contributed to study design and acted as nurse consultant in ProBE. KNLA and JMB carried out the preliminary qualitative study that highlighted locations of concern and contributed towards the ProBE study style. DEN advised on study priorities within ProBE, advised on integration in to the ongoing Shield study, and contributed to study design and style. All authors critically revised the manuscript and revised it for vital intellectual content material. JW will be the guarantor. All authors study and authorized the final manuscript. Acknowledgements The authors acknowledge the tremendous contributions for the ProBE (Prostate Biopsy Effects) Study Group of Prasad Bollina, Sue Bonnington, Lynn Bradshaw, Debbie Cooper, Liz Down, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pippa Herbert, Peter Holding, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Malcolm Mason, Hilary Moody, James N’Dow, Philip Powell, Alan Paul, Stephen Prescott, Patricia O’Sullivan, Pauline Thompson, and Sarah Tidball; and in addition for the Safeguard study group of James Catto, Michael Davis, Andrew Doble. The ProBE study was funded by the UK Prostate Cancer Threat Management Group. The Safeguard study is funded by the UK National Institute for Well being Research Health Technologies Assessment (NIHR HTA) Programme (Projects No. 96/20/ 06, 96/20/99) and can be published in full in Wellness Technology Assessment. JLD, FCH and DEN are NIHR senior investigators. The Good quality of Life in Protect study was funded by Cancer Study UK. The views and opinions expressed are these in the authors and don’t necessarily reflect those on the HTA programme, NIHR, Cancer Analysis UK, the NHS or the Department of Wellness. Author facts 1 School of Social and Neighborhood Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol BS8 2PS, UK. 2Academic Urology Unit, Royal Hallamshire Hospital, University of Sheffield, Sheffield S10 2JF, UK. 3Protect study Urology Research, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. 4Oncology Centre, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK. five Nuffield Departme.
